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Bianciotti, Liliana G., and Adolfo J. de Bold. Effect of
selective ETA receptor blockade on natriuretic peptide gene
expression in DOCA-salt hypertension. Am J Physiol Heart
Circ Physiol 279: H93–H101, 2000.—To determine the role of
endothelin-1 (ET-1) in the upregulation of atrial natriuretic
factor (ANF) and brain natriuretic peptide (BNP) observed in
deoxycorticosterone acetate (DOCA)-salt hypertension, the
selective ET-1 type-A receptor (ETA) antagonist ABT-627
was chronically administered to normal controls and hyper-
tensive rats. Chronic ETA blockade in DOCA-salt-treated
rats prevented the increase in blood pressure and circulating
natriuretic protein (NP) levels and partially prevented left
ventricular hypertrophy. The changes observed in NP gene
expression in the atria were not affected by ABT-627. In the
ventricles, ABT-627 reduced NP gene expression. Rats re-
ceiving the ETA antagonist alone showed reduced left ven-
tricular NP gene expression. ABT-627 did not affect ven-
tricular collagen III gene expression but enhanced left
ventricular a-myosin heavy chain expression. These findings
suggest that in vivo, ventricular but not atrial NP production
is regulated by ET-1. This difference in response between
atrial and ventricular NP gene expression to ETA receptor
blockade is similar to that observed by us after applying
angiotensin-converting enzyme inhibitors in other hyperten-
sive models. In general therefore, atrial NP gene expression
may not be as sensitive to the endocrine environment as is
ventricular NP gene expression.
atrial natriuretic factor; brain natriuretic peptide; ABT-627;
endothelin; hypertrophy
DEOXYCORTICOSTERONE ACETATE (DOCA)-salt treatment
powerfully stimulates cardiac gene expression of the
natriuretic peptides (NP), atrial natriuretic factor
(ANF), and brain natriuretic peptide (BNP) (9, 25).
Short-term (1 wk) DOCA-salt administration leads to
an increase in atrial NP gene expression, and a longer
treatment (5 wk) leads to an increase in ventricular NP
gene expression as well (25). The former effect is as-
cribed to volume expansion on stretch-stimulated gene
expression, whereas the latter effect is believed to arise
as a consequence of left ventricular hypertrophy and
associated activation of the cardiac fetal program re-
sulting from systemic hypertension. The mechanisms
underlying these changes in NP gene expression and
release remain unclear. We have previously shown
that mechanical and neuroendocrine factors indepen-
dently contribute to the modulation of ANF and BNP
ventricular gene expression. This view was advanced
based on the observation that in renovascular hyper-
tension, a low dose of the angiotensin-converting en-
zyme (ACE) inhibitor ramipril reverses hypertrophy
but does not decrease blood pressure and only partially
prevents enhanced ventricular NP gene expression
(16). These findings suggest that there are two compo-
nents that contribute to increased ventricular NP gene
expression: one occurs together with the hypertrophic
process and is independent of load, and another one is
dependent on hemodynamic load. Indeed, high-dose
ramipril, which also regresses hypertrophy but in ad-
dition normalizes blood pressure, completely normal-
ized ventricular NP gene expression. This investiga-
tion showed that atrial NP gene expression was not
affected by chronic treatment (of control or hyperten-
sive animals) with low- or high-dose ramipril, suggest-
ing that atrial and ventricular NP gene expressions are
differentially regulated (16).
Some of the effects of DOCA-salt treatment on NP
gene expression may be expected to arise from the
known activation of endothelin-1 (ET-1) in this hyper-
tension model (12). ET-1, signaling through the type-A
receptor (ETA) (24), induces significant changes in NP
gene expression and release both in vitro and in vivo (1,
2, 22). These findings suggest that ET-1 may be a key
factor in the maintenance of NP basal and stimulated
gene expression and release.
In the present work, we studied the effect of the
chronic blockade of the ETA receptor with a selective
ETA antagonist, ABT-627, on NP gene expression and
production in normal and DOCA-salt hypertensive
rats, to assess the contribution of ET-1 in mediating
basal and stimulated cardiac NP production in vivo. In
addition, we determined the levels of genetic expres-
sion of a- and b-myosin heavy chains (MHC) and col-
lagen III as independent molecular markers of hy-
pertrophy for cardiocytes and connective tissue, respec-
tively.
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MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 100–125 g were
housed under conditions of constant temperature and humid-
ity, with a 12-h light/dark cycle, and fed ad libitum. All
experiments were performed following the recommendations
of the Canadian Council for Animal Care. DOCA-salt hyper-
tension was induced with weekly subcutaneous injections of
30 mg/kg DOCA (Sigma) dissolved in sesame seed oil (as
vehicle) and the administration of 1% NaCl in the drinking
water for 5 wk. We administered 10 mg z kg21 z day21
ABT-627, the orally active enantiomer of the ETA blocker
A-12722 (18), in the drinking water. The dose was adjusted
daily based on water consumption and weight. After 5 wk,
systolic blood pressure was measured in conscious rats by tail
pletysmography (Narco Bio-Systems, Austin, TX), and the
average of three pressure readings was recorded. The ani-
mals were killed by decapitation, and trunk blood samples
were harvested into ice-cold tubes containing 0.1 ml of 15%
K3-EDTA. Blood samples were centrifuged at 2,000 g for 30
min at 4°C, and plasmas were kept at 280°C until assayed
for immunoreactive ANF and BNP. The hearts were rapidly
excised, and the four chambers were dissected, weighed,
rapidly frozen in liquid nitrogen and kept at 280°C. The
interatrial or interventricular septum was included with the
respective left chamber.
Total RNA extraction and Northern blot analysis. Total
RNA extraction and Northern blot analysis were performed
as previously described (16, 25). Briefly, total RNA was
extracted and electrophoretically separated in an agarose-
formaldeyde gel followed by blotting to nylon membranes
(Hybond N1, Amersham). Membranes were hybridized with
cDNA and oligonucleotide probes as detailed in previous
works (16, 25). The cDNA probes used were 1) a 900-bp EcoR
I/Hind III fragment containing the full-length rat ANF
cDNA, 2) a 595-bp Sal I fragment containing the full-length
BNP cDNA, 3) a 5-kb EcoR I/Sal I fragment of the mouse 28S
rRNA probe, 4) a 2-kb BamH I/Bgl II fragment of the mouse
phosphoglycerate kinase (PGK) gene cDNA, and 5) rat 1a-
collagen III cDNA containing 1,300 bp of the 39 noncoding
and coding regions. The two oligonucleotides used were 39-
and 24-base fragments specific for unique regions in the 39
untranslated regions of the rat a-MHC and b-MHC genes.
The cDNAs were labeled with 59 [a-32P]dCTP (3,000 Ci/
mmol, Amersham) using the Megaprime DNA labeling sys-
tem (Amersham). The oligonucleotides were labeled with
[g-32P]ATP (3,000 Ci/mmol, Amersham) using a 59 end-label-
ing kit (Amersham). Before additional probing, bound radio-
activity was stripped from the membranes by washing with
10 mM sodium citrate (pH 6.8) and 0.25% SDS at 100°C for
10 min. Autoradiographs were scanned using a laser densi-
tometer, and the scanning values for ANF, BNP, collagen III,
and MHC isoform mRNAs were normalized to 28S rRNA or
PKG mRNA to correct for differences in the amount of RNA
applied and for transfer efficiency.
Extraction and RIA for ANF and BNP in plasma and tissue
samples. NP were extracted from plasma and tissue samples
and assayed as previously described (16, 19, 20, 25). Anti-rat
ANF-(99–126) and anti-rat BNP-(64–95) serum were pur-
chased (Peninsula Laboratories, Belmont, CA) and showed
,0.01% cross-reactivity with BNP and ANF peptides, respec-
tively.
Analysis of results. Data are expressed as means 6 SE.
Statistical analysis was performed by ANOVA; a P value of
0.05 or less was considered statistically significant.
RESULTS
DOCA-salt-treated rats had a higher daily water
intake than control rats. The incorporation of the ETA
antagonist into the drinking water did not affect fluid
intake. The ETA antagonist intake was 10.4 6 0.2 mg z
kg21 z day21.
Systolic blood pressure, body weight, and heart
chamber weight. Systolic blood pressure was signifi-
cantly elevated in DOCA-salt-treated rats compared
with control rats and those treated with the ETA an-
tagonist (Table 1). Treatment with the ETA blocker
normalized blood pressure to control levels in DOCA-
salt-treated rats. ETA receptor blockade also reduced
systolic blood pressure in the rats receiving the antag-
onist alone. Body weight did not differ among the four
studied groups. The left ventricular weight-to-body
weight ratio (relative left ventricular weight) in DOCA-
salt hypertensive rats was increased compared with
controls and ETA-treated rats. DOCA-salt-treated rats
that received the ETA blocker showed a partial reduc-
tion in relative left ventricular weight. No modification
of the relative right ventricular weight was observed
among the studied groups.
Cardiac ANF and BNP gene expression. Figures 1
and 2 show cardiac NP gene expression in DOCA-salt-
treated rats with or without ETA receptor blockade.
ANF gene expression was enhanced in the left atrium
as well as in both ventricles of DOCA-salt-treated rats.
BNP gene expression was increased in all the cardiac
chambers in this group. The administration of the ETA
blocker partially prevented the increase of ANF and
BNP mRNA in the left ventricle, and totally prevented
it in the right ventricle. Atrial NP gene expression was
not affected by ETA receptor blockade. The group of
animals that received the antagonist alone had re-
duced left ventricular ANF and BNP gene expression
as compared with the control group.
a-MHC and b-MHC gene expression. DOCA-salt-
treated rats exhibited a reduction in a-MHC gene ex-
pression and an increase in b-MHC isoform in the left
ventricle (Figs. 3 and 4). However, no MHC isoform
switch was observed in the right ventricle. ETA recep-
tor blockade enhanced a-MHC expression but did not
Table 1. Effect of ETA receptor blockade on blood
pressure, body weight, and relative ventricular





BP, mmHg 11762 14963† 11062*‡ 12062§
BW, g 39467 39668 39966 39667
LVW/BW 2.0560.05 2.660.05† 2.160.06 2.460.06*§
RVW/BW 0.7660.03 0.7760.03 0.7760.02 0.7660.04
Values are means 6 SE of 12 independent observations. DOCA,
deoxycorticosterone acetate; ETA, endothelin-1 type-A receptor;
ABT-627, ETA antagonist; BP, systolic blood pressure; BW, body
weight; LVW/BW, relative left ventricular weight; RVW/BW, relative
right ventricular weight. *P , 0.05 vs. control; †P , 0.001 vs.
control; ‡P , 0.05 and §P , 0.01 vs. DOCA-salt.
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modify the expression of the b-isoform in the left ven-
tricle of DOCA-salt-treated rats or in the animals re-
ceiving only the antagonist (Fig. 4).
Collagen III gene expression. Collagen III mRNA, an
index of de novo connective tissue matrix synthesis,
was increased in the left ventricle of DOCA-salt-
treated rats but was not affected by the ETA receptor
blockade. No change in collagen III expression was
observed in the right ventricle in any of the groups
(Fig. 5).
Immunoreactive ANF and BNP plasma levels. DOCA-
salt treatment increased immunoreactive (ir) ANF and
BNP plasma concentrations (Fig. 6). The increase in
plasma BNP was significantly higher than that of ANF
(46% vs. 18%). ETA receptor blockade induced a signif-
icant reduction in plasma NP, this effect being most
marked for BNP.
Cardiac tissue irANF and irBNP. DOCA-salt-treated
rats exhibited a decrease in irANF in both right and
left atria and an increase in both ventricles (Fig. 7).
Treatment with ABT-627 reduced irANF in the right
ventricle to control levels but did not affect the peptide
content in the left ventricle or the atria. irBNP content
was not altered in the atria but was increased in the
right and left ventricles of DOCA-salt hypertensive
rats (Fig. 8). Treatment with ABT-627 totally pre-
vented the increase of irBNP in both ventricles.
DISCUSSION
The contribution of neuroendocrine factors to the
long-term regulation of ANF and BNP gene expression
in vivo remains poorly understood for both atria and
ventricles. The release of these hormones from the
atria is enhanced on stimulation by mechanical (mus-
cle stretch) or neuroendocrine (e.g., ET-1) stimuli.
Whether this stimulation results in an increase in NP
gene expression depends upon the duration and the
Fig. 1. Relative abundance of atrial natriuretic factor (ANF) transcripts in cardiac chambers after chronic
endothelin type A (ETA) receptor blockade (10 mg z kg
21 z day21 of ABT-627) in deoxycorticosterone acetate
(DOCA)-salt hypertensive rats. PGK, phosphoglycerate kinase. A: left atrium; B: left ventricle; C: right atrium; D:
right ventricle. Values are means 6 SE. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. control; §P , 0.05, §§P , 0.01,
and §§§P , 0.001 vs. DOCA-salt (n 5 4–5 rats).
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nature of the stimuli (1, 25, 26). For instance, DOCA-
salt treatment for 1 wk results in volume expansion
and leads to upregulation of NP gene expression that is
confined to the atria. In addition, 5 wk of DOCA-salt
treatment leads to hypertension, anatomical left ven-
tricular hypertrophy, and the activation of the cardiac
fetal program in the ventricles, which includes the
increased expression of genes encoding for a-skeletal
actin, ANF, and BNP, as well as to a switch in MHC
isoforms (3, 21, 25). Under these circumstances, BNP is
particularly upregulated in the ventricles. In the atria,
no MHC isoform switch is observed, despite the fact
that ANF and BNP gene expression is upregulated, as
is the case for the ventricles (25). In contrast, atrial
ANF and BNP gene expression in renovascular hyper-
tension remains unchanged, whereas ventricular ex-
pression does change in a manner that is partially
dependent on both the hypertrophic process and the
increase in hemodynamic load (25). These observations
show that the regulation of NP in atria and ventricles
differs significantly. In the present investigation, we
sought to establish the contribution of ET-1 to atrial
and ventricular NP gene expression in vivo through
the use of the selective ETA receptor antagonist ABT-
627 in DOCA-salt hypertensive rats. The DOCA-salt
model is known to be associated with upregulation of
the endothelin system as well as the NP system (12,
25). The pharmacological characterization of ABT-627
has been previously reported (18). It was found that 10
mg z kg21 z day21 was an effective oral dose to block the
effects elicited by ET-1 administration. Furthermore,
the effects induced by higher doses (30 mg z kg21 z
day21) were similar to those observed with the use of
10 mg z kg21 z day21 (18).
DOCA-salt treatment following the experimental de-
sign employed in the present work induced mild hyper-
tension, because the uninephrectomy necessary to in-
duce a severe hypertension was not performed.
However, the procedure employed is sufficient to
strongly upregulate cardiac NP gene expression.
Fig. 2. Relative abundance of brain natriuretic peptide (BNP) transcripts in cardiac chambers after chronic ETA
receptor blockade (10 mg z kg21 z day21 of ABT-627) in DOCA-salt hypertensive rats. A: left atrium; B: left ventricle;
C: right atrium; D: right ventricle. Values are means 6 SE. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. control;
§P , 0.05, §§P , 0.01, and §§§P , 0.001 vs. DOCA-salt (n 5 4–5).
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Blockade of the ETA receptor resulted in a significant
reduction of blood pressure, suggesting a role for ET-1
in the development of this type of hypertension. More-
over, rats receiving the ETA blocker alone exhibited
lower blood pressure than control rats. The latter ob-
servation supports a role for ET-1 in the regulation of
blood pressure under physiological conditions. Reduc-
tion of blood pressure in control animals has also been
reported after the administration of the selective ETA
antagonist FR-139317 (4).
ANF and BNP gene expression was increased in both
ventricles as well as in the left atria of DOCA-salt-
treated rats, confirming our previous findings (25). ETA
blockade partially prevented the increase in transcript
concentration induced by DOCA-salt in the left ventri-
cle and totally prevented it in the right ventricle. Nei-
ther ANF nor BNP atrial mRNA levels were affected by
ABT-627. In control animals, the administration of the
ETA antagonist decreased ANF and BNP gene expres-
sion in the left ventricle, suggesting that ET-1 plays a
role in the regulation of BNP gene expression in the
ventricles but not in the atria. Furthermore, these
findings suggest that ET-1 participates in the mainte-
nance of NP gene expression under physiological con-
ditions, because control rats treated with the blocker
alone showed significantly lower NP mRNA levels in
the left ventricle. It is not clear whether this is a purely
humoral effect, because the control rats treated with
the ETA blocker had significantly lower blood pressure
levels than control animals. Although blockade of the
ETA receptor led to a dramatic reduction of NP tran-
script concentration in the left ventricle of DOCA-salt
animals, it was not reduced to basal levels, suggesting
that factors other than ET-1 may participate in the
regulation and maintenance of the enhanced NP ex-
pression in chronic hemodynamic overload. This is in
line with our previous studies using the angiotensin-
converting enzyme (ACE) inhibitor ramipril. These
studies showed that there are two components that
determine ventricular NP concentration and transcript
levels: one is an ACE inhibitor-sensitive component
that accompanies anatomical hypertrophy, and the
other is a component that is dependent on hemody-
namic load (16). Under normal conditions, ANF is
secreted by the atria and BNP is released mainly by
the ventricles (17, 27). However, with chronic volume
or pressure overload, the ventricles actively produce
and release both ANF and BNP. Circulating levels of
Fig. 4. Relative abundance of b-MHC transcripts in the left (A) and
right (B) ventricles after chronic ETA receptor blockade (10 mg z
kg21 z day21 of ABT-627) in DOCA-salt hypertensive rats. Values are
means 6 SE. **P , 0.01 and ***P , 0.001 vs. control; §§§P , 0.001
vs. DOCA-salt (n 5 4–5).
Fig. 3. Relative abundance of a-myosin heavy chain (MHC) tran-
scripts in the left (A) and right (B) ventricles after chronic ETA
receptor blockade (10 mg z kg21 z day21 of ABT-627) in DOCA-salt
hypertensive rats. Values are means 6 SE. *P , 0.05, **P , 0.01,
and ***P , 0.001 vs. control; §P , 0.05 and §§§P , 0.001 vs.
DOCA-salt (n 5 4–5).
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ANF and BNP were elevated in DOCA-salt-treated
rats, which is in line with previous investigations (25).
The increase in circulating BNP was considerably
higher than that of ANF (46% vs. 18%). ETA receptor
blockade resulted in a reduction of plasma ANF and
BNP to near control levels. The decrease in circulating
NP induced by the ETA antagonist was mirrored by
changes in ventricular NP gene expression and con-
tent, as well as by changes in blood pressure. DOCA-
salt-treated rats that were also treated with the ETA
antagonist were normotensive. These results suggest
that the reduction of circulating NP in DOCA-salt-
treated rats that were also treated with ABT-627 may
be the result of the reduction of NP gene expression as
well as the normalization of blood pressure promoted
by ETA blockade. Such association between NP gene
expression and circulating NP levels has also been
reported in renovascular hypertension (11). DOCA-
salt-treated rats exhibited a significant reduction of
irANF in both atria and an increase in the right and
left ventricles. The reduction of irANF in the right
atria was not accompanied by an increase in ANF gene
expression as it occurs in the left atria. We have pre-
viously observed a similar depletion of ANF stores
without increase in mRNA steady-state levels during
mineralocorticoid escape. Continued mineralocorticoid
treatment, however, resulted in increased mRNA lev-
els (26). These studies and the investigations reported
here indicate that despite the upregulation of ET-1
gene expression, ANF mRNA levels rise only after a
critically diminished level of stored hormone is
reached. In contrast, ventricular irANF as well as
mRNA levels were increased in DOCA-salt hyperten-
sive rats and significantly reduced by ETA receptor
blockade. These changes were reflected in the circulat-
ing levels of ANF, suggesting that ET-1 plays a signif-
icant role in the regulation of ANF production and gene
expression in the ventricles but not in the atria.
In DOCA-salt-treated rats, BNP content was not
modified in either left or right atria; in contrast, it was
increased in both ventricles and reduced by ETA recep-
tor blockade. Changes in BNP gene expression were
accompanied by similar changes in irBNP in both ven-
tricles. Moreover, these changes were reflected in cir-
culating BNP levels. These findings suggest that the
majority of circulating BNP is derived from the ventri-
cles and that the synthesis and release of this NP is
regulated by ET-1.
A significant left ventricular hypertrophy occurred in
DOCA-salt-treated rats, which was partially reduced
by the ETA receptor blockade. The potential role of
ET-1 in the development and maintenance of cardiac
hypertrophy is strongly supported by the fact that
ET-1 is a potent growth-promoting factor: it induces
DNA synthesis and proliferation of smooth muscle
cells, fibroblasts, and hypertrophy of cardiocytes (7,
15). ETA and ETB receptors have been implicated in
the pathogenesis of myocardial hypertrophy (13, 15). In
cultured ventricular myocytes, incorporation of phe-
nylalanine into cellular protein in response to ET-1 has
been reported to be significantly attenuated in the
presence of selective antagonists for ETA and ETB
receptors (13). Because both receptors have been im-
plicated in the pathogenesis of left ventricular hyper-
trophy, this could account for the fact that the admin-
Fig. 6. Plasma ANF (open bars) and BNP (filled bars) after ETA
receptor blockade (10 mg z kg21 z day21 of ABT-627) in DOCA-salt
hypertensive rats. Values are means 6 SE. *P , 0.05 and ***P ,
0.001 vs. control; §P , 0.05 and §§§P , 0.001 vs. DOCA-salt (n 5
10–12).
Fig. 5. Relative abundance of collagen III (Coll III) transcripts in the
left (A) and right (B) ventricles after chronic ETA receptor blockade
(10 mg z kg21 z day21 of ABT-627) in DOCA-salt hypertensive rats.
Values are means 6 SE. *P , 0.05 and **P , 0.01 vs. control (n 5
4–5).
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istration of a highly selective ETA blocker causes only
a partial regression of left ventricular hypertrophy in
the DOCA-salt-treated rat. However, the administra-
tion of bosentan (ETA/ETB receptor antagonist) also
causes partial regression of left ventricular hypertro-
phy in the same experimental model. In aortic-banded
rats, the treatment with BQ-123, a selective ETA
blocker, induced regression of hypertrophy after 1 wk
of banding, although the effect was no longer evident
after 2 wk of banding (8). From these findings it was
concluded that ET-1 might be relevant in triggering
rather than in maintaining the hypertrophic response
to hemodynamic overload. In the present study, how-
ever, a partial regression of ventricular hypertrophy
was evident even after 5 wk of treatment with the
antagonist. Taken together, these results support a
role for ET-1 not only in triggering but also in the
maintenance of cardiac hypertrophy. Partial regres-
sion of left ventricular hypertrophy in the presence of
ET-1 antagonisms strongly supports the participation
of other factors in the cardiac hypertrophic response to
hemodynamic overload. Several reports support the
existence of a cross-talk interaction between ANG II
and ET-1 in the hypertrophic response. ANG II would
thus stimulate (through the ANG II type 1, or AT1
receptor) ET-1 gene expression and content in the
heart and in blood vessels (6, 14). Moreover, ET-1
receptor antagonists inhibit the mitogenic effect of
ANG II on cardiomyocytes and blood vessels (14). Fur-
thermore, A1 receptor antagonists reduce ET-1 overex-
pression in renin transgenic rats (23).
Ventricular hypertrophy is characterized by the re-
expression of the cardiac fetal gene program, which
includes modifications in MHC content. In the present
study, DOCA-salt treatment induced a relative in-
crease in b-MHC gene expression and a decrease in
a-MHC transcript abundance. ETA receptor blockade
did not change b-MHC expression, but it increased
a-MHC gene expression, suggesting that ET-1 selec-
tively regulates a-MHC gene expression. In the
present study, neither anatomic hypertrophy nor MHC
isoform switch occurred in the right ventricle, but
Fig. 7. Cardiac immunoreactive (ir) ANF after chronic ETA receptor blockade (10 mg z kg
21 z day21 of ABT-627) in
DOCA-salt hypertensive rats. A: left atrium; B: left ventricle; C: right atrium; and D: right ventricle. Values are
means 6 SE. *P , 0.05 and **P , 0.01 vs. control; §P , 0.05 and §§P , 0.01 vs. DOCA-salt (n 5 4–5).
H99NP GENE EXPRESSION AND ETA RECEPTOR BLOCKADE
there was an enhancement of NP gene expression. We
previously reported similar findings in renovascular
hypertensive rats (16); i.e., increased right ventricular
NP gene expression without either anatomic hypertro-
phy or MHC isoform switch. These findings support the
view that enhanced NP gene expression may coexist
with hypertrophy but that it is not necessarily depen-
dent on this process. During cardiac hypertrophy pro-
gression, fibrillar collagen content of the ventricle in-
creases as the result of the activation of interstitial
fibroblasts. In the present investigation, collagen III
gene expression was markedly increased in the left
ventricle, but it was not affected by ETA receptor block-
ade. This finding suggests that ET-1 does not signal
through the ETA receptor in the activation of cardiac
fibroblasts responsible for the increased collagen III
production. Cardiac fibroblasts have been reported to
possess ETA and ETB receptor subtypes, the latter
being predominant (10). Both ET-1 and ET-3 were
reported to be similar in their ability to stimulate the
synthesis of fibrillar collagen, which suggests the in-
volvement of both types of receptors, because the ETA
receptor is selective for ET-1 (5). However, the utiliza-
tion of PED-3512-PI, a specific antagonist for the ETA
receptor, failed to suppress the stimulatory effect of
ET-1 on collagen synthesis (5). In conclusion, our re-
sults show that in DOCA-salt hypertension, ET-1 plays
a role in the regulation of chronically enhanced NP
gene expression and production in the ventricles, but
not in the atria, and this suggests the participation of
other regulating factors. ET-1 is also a mediator in the
development of hypertension and ventricular hypertro-
phy and in the downregulation of a-MHC expression.
Our findings further support the hypothesis that al-
though ventricular hypertrophy, enhanced NP produc-
tion, and MHC isoform switch are present in chronic
hemodynamic load, they are processes that can be
dissociated and seem to be differentially regulated.
Furthermore, NP synthesis and production in the atria
appear to be regulated by changes in the hemodynamic
load rather than by changes in the endocrine environ-
ment. Ventricular synthesis and production of NP, on
Fig. 8. Cardiac irBNP after chronic ETA receptor blockade (10 mg z kg
21 z day21 of ABT-627) in DOCA-salt
hypertensive rats. A: left atrium; B: left ventricle; C: right atrium; D: right ventricle. Values are means 6 SE. **P ,
0.01 vs. control; §P , 0.05, §§P , 0.01, and §§§P , 0.001 vs. DOCA-salt (n 5 4–5).
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the other hand, appear to be influenced by the cardiac
neurohormonal environment.
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